U.S. FDA Approved Sanofi’s Qfitlia to Treat Hemophilia
In order to help hemophiliacs regain hemostasis, Qfitlia helps boost thrombin production by decreasing AT, a protein that prevents blood clotting.
Category: Healthcare & Pharmaceuticals
Eli Lilly Responds to EMA’s Donanemab Marketing Authorization Rejection
Eli Lilly and Company’s (LLY) donanemab is not recommended for marketing authorization for the treatment of early symptomatic Alzheimer’s disease, according to an opinion released [Read More…]
Bayer and Puhe BioPharma With Global License Agreement For Clinical Phase I PRMT5 Inhibitor for Brain Tumors
For the clinical phase, Bayer has acquired the sole global license for an MTA-cooperative PRMT5 inhibitor that targets MTAP-deleted tumors selectively.
U.S. FDA Approved GSK’s Blujepa (gepotidacin) for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) for Female Adults and Paediatric Patients 12 years of Age and Older
Approval based on data from the pivotal phase III EAGLE-2 and EAGLE-3 trials.
Opthea Released COAST Phase 3 Clinical Trial Results
articipants receiving sozinibercept combination therapy with a dosing regimen of every four weeks or every eight weeks.
Insulet Released RADIANT Trial Results of Their Omnipod® 5 Automated Insulin Delivery System
In addition to being the first to examine the safety and effectiveness of an automated insulin delivery (AID) system in conjunction with an Abbott FreeStyle Libre® 2 family sensor
Eli Lilly Launches Their Blockbuster Weight-loss and Diabetes Drug Mounjaro in India
Mounjaro, the First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes.
GSK Released EMBRACE a Phase 2b Clinical Trial Data of an Investigational Broadly Neutralising Antibody for HIV
The findings support the increasing amount of data showing that N6LS is a strong antiviral that may be used as part of an all-encompassing antiretroviral treatment plan.
AstraZeneca Released Satisfactory Results of 24 Weeks CALYPSO Phase III Trial for Eneboparatide
Trial continues as planned to 52 weeks to further characterize the risk-benefit profile.
Engineers Converted Skin Cells to Neurons for Cell Therapy Purpose
The researchers created a highly effective conversion technique using mouse cells that can generate over ten neurons from a single skin cell.
